Page 2 of 2 FirstFirst 12
Results 11 to 13 of 13

Thread: Dr Young: Status on Acorda's Famipridine?

  1. #11
    Quote Originally Posted by Zero
    Does this drug counteract other drugs that suppress neural activity, like baclofen and gabapentin? Can these three drugs be taken together?
    Zero, the clinical trials gave the drug alongside baclofen and did not seem to antagonize the baclofen. I don't know any data conerning interaction of how many patients were taking gabapentin.


  2. #12
    Quote Originally Posted by George78
    Hello Dr. Young and thanks for the update. Are those differents therapies available today for human and FDA approved?.. Can you please tell us how we can evaluate how demyelinated our spinal cord are?..
    Many thanks
    George, as you know, there has been a dearth of clinical trials for SCI and many of these therapies are awaiting clinical trials. However, they may be tested in MS trials. The NIH and MS Society have a lot more MS trials going.


  3. #13

    PharmaLive: Acorda Therapeutics to Present Phase 3 Fampridine-SR Data at World Congre

    PharmaLive: Acorda Therapeutics to Present Phase 3 Fampridine-SR Data at World Congress on Treatment and Research in MS Meeting
    September 12th, 2008 | by admin |

    HAWTHORNE, N.Y.–(BUSINESS WIRE)–Sep 12, 2008 - Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that data from its recently-completed Fampridine-SR Phase 3 trial (MS-F204) will be presented during a poster session at the World Congress in Treatment and Research in MS Meeting (ACTRIMS, ECTRIMS and LACTRIMS) on Saturday, September 20, 2008 in Montreal, Canada. The Company previously announced top-line data from MS-F204 on June 2, 2008, and the poster will provide additional data from that clinical trial.


Similar Threads

  1. Replies: 13
    Last Post: 12-14-2003, 04:23 PM

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts